Live Breaking News & Updates on Animal Health Revenue

Stay updated with breaking news from Animal health revenue. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Merck Announces First-Quarter 2021 Financial Results


Merck Announces First-Quarter 2021 Financial Results
First-Quarter 2021 Sales Were $12.1 Billion, In-Line with First-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Declined 1% First-Quarter 2021 Sales Reflect Strong Underlying Performance of KEYTRUDA, Lynparza, BRIDION and Animal Health, Which Was Offset by COVID-19 Pandemic Impacts to Patient Access, Particularly for Vaccines First-Quarter 2021 GAAP EPS Was $1.25; First-Quarter Non-GAAP EPS Was $1.40 …
First-Quarter 2021 Sales Were $12.1 Billion, In-Line with First-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Declined 1%
First-Quarter 2021 Sales Reflect Strong Underlying Performance of KEYTRUDA, Lynparza, BRIDION and Animal Health, Which Was Offset by COVID-19 Pandemic Impacts to Patient Access, Particularly for Vaccines
First-Quarter 2021 GAAP EPS Was $1.25; First-Quarter Non-GAAP EPS Was $1.40 ....

United States , Patrick Ryan , Implanon Nexplanon , Cozaar Hyzaar , Kennethc Frazier , Ridgeback Biotherapeutics , Robertm Davis , Peter Dannenbaum , Pandion Therapeutics Inc , American Society For Clinical Oncology , Merck Co , Acquisition Of Pandion Therapeutics Inc , Gilead Sciences Inc , Statement Of Merck Co Inc , Merck Co Inc , Animal Health Revenue , Society Of Gynecologic Oncology , Alydia Health , Foreign Exchange Of Less Than , Women Health , Drug Administration , European Commission , Data Monitoring Committee , Exchange Commission , Eisai Co Ltd , Alliance Revenue ,

Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results


Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results
Fourth-Quarter 2020 Worldwide Sales Were $12.5 Billion, an Increase of 5% Fourth-Quarter 2020 GAAP Loss per Share Was $0.83, Reflecting Charges Related to Acquisitions and Intangible Asset Impairments; Fourth-Quarter Non-GAAP EPS Was $1.32 Full-Year 2020 Worldwide Sales Were $48.0 Billion, an Increase of 2%; Excluding the Impact from Foreign Exchange, Sales Grew 4% KEYTRUDA 2020 Worldwide Sales Grew 30% to $14.4 …
Fourth-Quarter 2020 Worldwide Sales Were $12.5 Billion, an Increase of 5%
Fourth-Quarter 2020 GAAP Loss per Share Was $0.83, Reflecting Charges Related to Acquisitions and Intangible Asset Impairments; Fourth-Quarter Non-GAAP EPS Was $1.32
Full-Year 2020 Worldwide Sales Were $48.0 Billion, an Increase of 2%; Excluding the Impact from Foreign Exchange, Sales Grew 4%
KEYTRUDA 2020 Worldwide Sales Grew 30% to $14.4 Billion ....

United States , Michael Decarbo , Kennethc Frazier , Peter Dannenbaum , Patrick Ryan , Implanon Nexplanon , Cozaar Hyzaar , Us Centers For Disease , Merck Foundation , Merck Co Inc , Peloton Therapeutics Inc , Women Health , Drug Administration , Seagen Inc , Exchange Commission , Organon Co , Net Income Attributable To Merck Co Inc , Business Development , Arqule Inc , Merck Co , Melinda Gates Foundation , Statement Of Merck Co Inc , Cubist Pharmaceuticals Inc , Animal Health Revenue , European Union , Bayer Ag ,